BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services Pre-Clinical Outsourcing

Single-Use Systems Are Rewiring Biopharma Manufacturing

Bioprocess, Unbottled Single-use systems (SUS) have become a transformative force in biopharmaceutical processing, offering an alternative to trad...

September 16, 2025 | Report

AGC Biologics Seattle Site Achieves New Heights in Manufacturing Excellence

Manufacturing excellence positions Seattle site as premier destination for mammalian and microbial biologic production in thriving Pacific Northwest life...

September 11, 2025 | News

KBI Biopharma and Infinimmune Partner to Advance Manufacturing of Lead Human-First Antibody IFX-101

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotec...

September 09, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

WuXi XDC Delivers 62% Revenue Growth and Record Project Momentum in H1 2025

- Revenue increased by 62.2% YoY to RMB 2,701 million - Gross profit surged by 82.2% YoY to RMB 975 million, with i...

August 19, 2025 | Company results

WuXi Biologics Achieves Fully Automated Continuous Drug Substance Manufacturing at Pilot Scale with WuXiUP™ Platform

Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the ...

August 13, 2025 | News

PolyActiva Launches U.S. Trial of Glaucoma Implant Following Australia Success

PA5108, a new chemical entity, is an investigational, biodegradable ocular micro implant, designed to deliver sustained intraocular pressure control for ...

August 08, 2025 | News

Bridging Real-World Evidence and AI: Unlocking Smarter, Faster Clinical Research in Asia

Having worked with pharma clients, healthcare providers, and digital platforms across the Asia-Pacific region, I’ve seen the challenges first-hand&md...

August 04, 2025 | Opinion

I Peace and Vita Therapeutics Partner to Develop Universal Hypoimmune iPSC Lines for Cell Therapy

Leading GMP cell CDMO I Peace, Inc. specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the co...

July 11, 2025 | News

WuXi Biologics Launches WuXiHigh™2.0 to Enable Record-Setting High-Concentration Biologic Formulations

The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces visc...

July 01, 2025 | News

Porton Advanced Supports IND Approval of Tasly’s Dual-Targeting CAR-T Therapy for Recurrent Glioblastoma

Porton Advanced proudly announces its CDMO support for Tasly Pharmaceutical Co., Ltd.'s innovative CAR-T therapy, "P134 Cell Injection," which has received...

April 17, 2025 | News

TCI Biotech Elevates CDMO+ Services with US-Based Glass Bottling for Liquid Supplements

TCI Biotech (TCI Co., Ltd.), a CDMO+ organization specializing in health and wellness products, is spotlighting its comprehensive US-based glass bottling s...

April 03, 2025 | News

Chance Pharmaceuticals Secures New Funding to Advance Phase III Trials for CXG87 and Expand Inhalation Therapy Pipeline

Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapi...

March 18, 2025 | News

WuXi Biologics Introduces EffiX™ a High-Yield E. coli Expression Platform for Recombinant Proteins and Plasmid DNA Production

EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. ...

March 04, 2025 | News

Stay Connected